Securities code: 002872 securities abbreviation: St Tiansheng Announcement No.: 2022-005
Tiansheng Pharmaceutical Group Co.Ltd(002872)
2021 annual performance forecast
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete
False records, misleading statements or material omissions.
1、 Expected performance of the current period
1. Performance forecast period: January 1, 2021 to December 31, 2021
2. Performance forecast: \uf0fe
Same period last year
Current reporting period of the project
Before and after reorganization
Loss attributable to listed companies: 38 million yuan – 75 million yuan; loss: 490732400 yuan; loss: 467377800 yuan; net profit of shareholders: million yuan
Net profit after deducting non recurring loss: 72 million yuan – 115 million yuan loss: 147.3083 million yuan loss: 136.6111 million yuan profit
Loss of basic earnings per share: 0.1195 yuan / share – 0.2358 loss: 1.5432 yuan / share loss: 1.4697 yuan / share
Operating income of 710 million yuan – 750 million yuan 1202.7461 million yuan 464.0604 million yuan
After deduction, the operating income is 70 million yuan – 735 million yuan, 1179.7755 million yuan and 441.6883 million yuan
Note: ① the “Yuan” in this format is RMB. ② Operating income after deduction refers to the main business after deduction
Operating income after irrelevant business income and income without commercial substance. ③ During the reporting period, the company completed the implementation of the re
Large asset restructuring, the company completed Chongqing pharmaceutical group Changsheng Pharmaceutical Co., Ltd. (hereinafter referred to as “Changsheng”) on April 29, 2021
“Changsheng pharmaceutical”) 51% equity transfer procedures and industrial and commercial change registration procedures, Chongqing pharmaceutical group Changsheng Pharmaceutical Co., Ltd
51% equity of the company has been transferred and registered under the name of Chongqing pharmaceutical (Group) Co., Ltd. After restructuring in the same period of last year in the above table
The data is calculated from the scope of consolidated statements after the completion of simulated restructuring.
2、 Communication with accounting firms
The financial data related to the performance forecast in the reporting period has not been pre audited by the accounting firm. The company has pre communicated with the certified public accountants who signed the accounting firm providing annual audit services for the company on this performance forecast. As the audit of the 2021 annual report is still in progress, so far, there is no significant difference between the two sides on this performance forecast, and the specific data shall be subject to the audit results.
3、 Explanation of performance change reasons
1. The company made provision for impairment of large assets in the previous year, including fixed assets, construction in progress and intangible assets. According to the preliminary evaluation results, there was no major change in these assets in the current year, so the asset impairment in the current year was significantly less than that in the previous year.
2. On April 29, 2021, the company transferred 51% of the equity of Chongqing pharmaceutical group Changsheng Pharmaceutical Co., Ltd. to Chongqing pharmaceutical (Group) Co., Ltd., resulting in the reduction of the scope of the company’s consolidated statements and the decrease of operating revenue compared with the previous year.
3. In order to build a marketing system, strengthen the construction of marketing team and the promotion of professional chemistry, the company has invested high sales expenses, which has not produced significant results at present; The company’s fixed expenses such as asset depreciation expense and labor cost are high, resulting in loss of operating performance.
4、 Other relevant instructions
This performance forecast is the result of the preliminary calculation of the company’s financial department. The specific financial data shall be subject to the 2021 annual report disclosed by the company. Please make careful decisions and pay attention to investment risks.
It is hereby announced.
Tiansheng Pharmaceutical Group Co.Ltd(002872) board of directors
January 28, 2022
